Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Immunodiagnostic Systems warned its first-quarter results would be 'significantly impacted' by reduced laboratory testing volumes owing to the ongoing Covid-19 pandemic.
The company said, however, it was in a 'strong position' to continue revenue growth once the pandemic had subsided.
The sombre update arrived as the company reported a jump in annual profit driven by an increase in revenue and finance income.
For the year ended 31 March 2020, pre-tax profit jumped to £3.2m from 842K as revenue increased 2% to £39.3m.
Net finance income was £1.9m, up from £0.4m on-year.
Looking ahead, the company said it would continue with plans to commercialise its range of automated and manual SARS-CoV-2 antibody testing kits, which it expected to launch during June 2020.
At 9:09am: (LON:IDH) Immunodiagnostic Systems Holdings PLC share price was -10p at 265p